Green Tea Extract for Endometriosis Treatment

Phase 2

Completed

• Conditions: Endometriosis
• Interventions: Drug: SUNPHENON EGCg; Drug: Placebo

• Registration Number: NCT02832271
• Lead Sponsor: Chinese University of Hong Kong

Brief Summary

The purpose of the study is to evaluate the efficacy and safety of green tea in endometriosis.

Detailed Description

Women with endometrioma will be randomised into either the experimental group or the placebo comparator group in a 1:1 ratio. The subjects will be given SUNPHENON EGCg or placebo for 3 months prior to their planned surgery.

Study Timeline

• Study First Submitted: 2016-07-05
• Study First Submitted QC: 2016-07-11
• Study First Posted: 2016-07-14
• Study Start: 2016-12-08
• Primary Completion: 2022-12
• Study Completion: 2022-12
• Status Verified: 2023-02
• Last Update Submitted: 2023-02-06
• Last Update Posted: 2023-02-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 185

Inclusion Criteria

• Complaints of pelvic pain, dysmenorrhoea and/or dyspareunia ≥ 6 months; and
• Verbal pain rating scale > 4/10 and visual analogue pain scale > 4cm; and
• Ultrasound confirmed endometrioma with or without fibroid and adenomyoma; and
• Planned surgery treatment within 4-6 months

Read More

Exclusion Criteria

• Age < 20 years beyond or >40 year behind the active reproductive age; or
• BMI <18.5 kg/m2 as underweight or >25 kg/m2 as overweight; or
• Chronic pelvic pain or low back pain due to other medical conditions, e.g. urological disorders and orthopaedic disorders; or
• Secondary dysmenorrhoea due to gynaecological conditions other than endometriosis, e.g. pelvic inflammatory diseases, genitourinary infections, gynaecological tumours, etc.; or
• Primary dysmenorrhoea without any underlying disease identified; or
• Ultrasound suggested polycystic ovary, haemorrhagic ovarian cyst, ovarian dermoid cyst, cystic neoplasm, tubo-ovarian abscess or other ovarian pathologies in the same ovary; or
• Chronic medical conditions under long-term medications; or
• Endometriosis under active medication in past 1 month; or
• History of herbal medicine intake in past 1 month

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
green tea group	SUNPHENON EGCg	green tea extract SUNPHENON EGCg for women with ultrasound confirmed endometriosis
placebo group	Placebo	placebo fro women with ultrasound confirmed endometriosis

Primary Outcome Measures

Name	Time	Method
Change in endometriotic lesion size	At 0 and 3 months of treatment	Structural MRI will be performed with a 3T whole-body clinical scanner by a radiologist. The total volume of endometriotic mass in the endometrioma indicated by the positive enhanced image will be quantified. The endometriotic mass before treatment will be used as baseline for comparison and analysis. Prior to the planned surgery, another structural MRI will be performed again to assess the changes in endometriotic mass after treatment.

Secondary Outcome Measures

Name	Time	Method
Number of Participants with adverse outcome and side effects	At 0, 1.5 and 3 months of treatment	any related and unrelated severe adverse events and adverse events, side-effects
Changes in pain scores assessed by ESS and VAS	At 0, 1.5 and 3 months of treatment	The severity of the pain will be quantified and evaluated by an Endometriosis Symptom Severity verbal rating scale (ESS). With ESS, subjects will rate their pain from score 0 as absence of pain to 10 as the most severe intolerable pain. A modified Biberoglu-Behrman 10cm visual analogue scale (VAS) will also be used to evaluate the pain experienced by the subjects. For VAS, subjects will mark the level of pain that they encounter on a graphic scale which range from 0cm as absence of pain to 10cm as the pain becomes as bad as it could possibly be. The 2 measurements will be recorded separately.
Changes in quality of life assessed by SF36	At 0, 1.5 and 3 months of treatment	Quality of life will be assessed using the standard SF36 instrument. SF36 consists of a medical survey which consists of 8 domains. The domain scores are rated onto a scale from 0 as worst health to 100 as best health. The Endometriosis Health Profile version 5 (EHP5) will as well be used to assess the quality of life. EHP5 contains 5 core and 6 modular questionnaires. Each item is rated on a 5-point scale (from 0=never to 4=always). The overall score will be transformed to a scale of 0 as best health and 100 as worst health.
Change in endometriotic growth assessed by pathology	At 0 and 3 months of treatment	Endometriotic cysts biopsies will be collected during the surgery. Endometriotic growth will be confirmed by the presence of endometrial epithelial glands and stroma in the biopsies. The biopsies will be compared to the endometriotic mass before treatment.
Change in total number of neovasculatures assessed by DCE-MRI	At 0 and 3 months of treatment	Subjects will undergo pelvic DCE-MRI for measurement of the total number of neovasculatures in the endometriotic mass.
Change in density of neovasculatures assessed by DCE-MRI	At 0 and 3 months of treatments	Subjects will undergo pelvic DCE-MRI for measurement of the density of neovasculatures in the endometriotic mass.

Trial Locations

Locations (1)

Prince of Wales Hospital; 🇭🇰 Shatin, Hong Kong